Book reviews |
| |
Authors: | Mike Gardner |
| |
Affiliation: | (1) Molecular Angiogenesis Laboratory, Cancer Research UK, Weatherall Inst. Molecular Medicine, University of Oxford, John Radcliffe Hospital, OX3 9DS Headington, Oxford, UK |
| |
Abstract: | Angiogenesis, or the growth of new blood vessels, has, in recent years, become an area of intense scientific research. The primary reason for this has been the realization that angiogenesis plays a key role in many common pathologies, and that its inhibition could have profoound implications in the treatment of these disorders. A substantial number of anti-angiogenic agents have now been identified; however, none has, as of yet, achieved widespread acceptance in the clinic. Many agents have been identified as the result of clearly defined research programs, such as the inhibitors of the vascular endothelial growth factor transmembrane tyrosine kinase receptors, but many other simply by screening. The purpose of this article is to reveiw the wealth of information available on known anti-angiogenic agents and to assess their future potential. |
| |
Keywords: | Angiogenesis anti-angiogenesis angiogenic inhibitor endothelial cell microvascular density vascular disease cancer targeting delivery dormany regression clinical trial |
本文献已被 PubMed SpringerLink 等数据库收录! |
|